Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Newron Pharmaceuticals SpA
Discovers and develops small molecule drugs

Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain.

The focus of its treatments includes patients with Parkinson's disease, Rett Syndrome, Amyotrophic Lateral Sclerosis, schizoprenia, and neuropathic pain.

The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Number of employees : 23 persons.
Sales per Businesses
20152016Delta
CHF (in Million)%CHF (in Million)%
Pharmaceutical Drugs2.43100%5.16100% +112.52%
Sales per Regions
20152016Delta
CHF (in Million)%CHF (in Million)%
Global2.43100%5.16100% +112.52%
Managers
NameAgeSinceTitle
Stefan Weber522005Chief Executive Officer, Director & IR Contact
Ulrich Köstlin, PhD652013Non-Executive Chairman
Roberto Galli-2002Vice President-Finance
Ravi Anand, MD602005Chief Medical Officer
Patrick J. Langlois, PhD722008Independent Non-Executive Director
Robert Leslie Holland MD, PhD622013Independent Non-Executive Director
Bo Jesper Hansen MD, PhD592013Independent Non-Executive Director
Joseph Donald deBethizy, PhD662014Independent Non-Executive Director
Luca Benatti, PhD562014Independent Non-Executive Director
Marco Caremi602002Executive Vice President-Business Development
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 17,837,345 14,177,422 79.5% 0 0.0% 79.5%
Shareholders
NameEquities%
Investor AB 1,670,317 9.37%
Aviva Plc 1,258,251 7.06%
Gefim SpA 785,448 4.41%
JPMorgan Asset Management (UK) Ltd. 311,633 1.75%
UBS AG (Investment Management) 270,195 1.52%
Union Investment Privatfonds GmbH 149,140 0.84%
Polar Capital LLP 148,573 0.83%
Kairos Partners SGR SpA 140,422 0.79%
EFG Asset Management (UK) Ltd. 137,500 0.77%
Norges Bank Investment Management 121,793 0.68%
Company contact information
Newron Pharmaceuticals SpA
via Ludovico Ariosto 21
Bresso, Milan 20091

Phone : +39.02.610.3461
Fax : +39.02.610.34654
Web : www.newron.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS SPA-38.96%224
GILEAD SCIENCES1.69%95 098
REGENERON PHARMACEUTICALS4.73%41 637
VERTEX PHARMACEUTICALS99.59%37 187
GENMAB4.94%11 692
EXELIXIS, INC.74.72%7 731
BLUEBIRD BIO INC171.07%7 663
JUNO THERAPEUTICS INC211.78%6 888
NEUROCRINE BIOSCIENCES, INC.91.71%6 355
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.8.48%6 099
BIOVERATIV INC0.00%5 436
TESARO INC-37.60%4 563
HUALAN BIOLOGICAL ENGINEERING INC--.--%4 299
BEIGENE LTD (ADR)183.53%3 914
PEPTIDREAM INC-41.94%3 811
BIOCON LTD32.74%3 785
BEIJING SL PHARMACEUTICAL CO LTD--.--%3 634
SAREPTA THERAPEUTICS INC103.61%3 634
AVEXIS INC101.11%3 073
CLOVIS ONCOLOGY INC37.71%3 015
AGIOS PHARMACEUTICALS INC44.21%2 989
Connections : Newron Pharmaceuticals SpA
European School of Management & Technology GmbH
White City Consulting ApS
DFC Langlois
PJL Consulting
Oxford Gene Technology IP Ltd.
Early Clinical Development Consulting Ltd.
Proterris, Inc.
LABORIE Medical Technologies, Inc.
Wellington Partners GmbH
EryDel SpA
Constantia Flexibles Group GmbH
Constantia Flexibles AG
Universitätsklinikum Würzburg
Azanta A/S
NOXXON Pharma AG
Assobiotec
Italian Angels For Biotech
MipSalus ApS
Orphazyme A/S
The European Association for Bioindustries
© 2017 People , Fundamentals and Ownership